as of 12-12-2025 3:41pm EST
Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain.
| Founded: | 1996 | Country: | Canada |
| Employees: | N/A | City: | BURNABY |
| Market Cap: | 3.4B | IPO Year: | 2014 |
| Target Price: | $53.91 | AVG Volume (30 days): | 768.3K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 11 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.89 | EPS Growth: | N/A |
| 52 Week Low/High: | $26.74 - $46.60 | Next Earning Date: | 11-03-2025 |
| Revenue: | $7,500,000 | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | -33.61% |
Machine learning model trained on 25+ technical indicators
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
PRESIDENT & CEO
Avg Cost/Share
$45.96
Shares
10,830
Total Value
$495,207.00
Owned After
8,010
PRESIDENT & CEO
Avg Cost/Share
$45.03
Shares
14,375
Total Value
$647,306.25
Owned After
8,010
SEC Form 4
PRESIDENT & CEO
Avg Cost/Share
$45.01
Shares
97
Total Value
$4,365.97
Owned After
8,010
SEC Form 4
PRESIDENT, CEO & INTERIM CFO
Avg Cost/Share
$40.16
Shares
25,000
Total Value
$1,004,000.00
Owned After
8,010
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| MORTIMER IAN | XENE | PRESIDENT & CEO | Dec 8, 2025 | Sell | $45.96 | 10,830 | $495,207.00 | 8,010 | |
| MORTIMER IAN | XENE | PRESIDENT & CEO | Dec 5, 2025 | Sell | $45.03 | 14,375 | $647,306.25 | 8,010 | |
| MORTIMER IAN | XENE | PRESIDENT & CEO | Nov 28, 2025 | Sell | $45.01 | 97 | $4,365.97 | 8,010 | |
| MORTIMER IAN | XENE | PRESIDENT, CEO & INTERIM CFO | Oct 1, 2025 | Sell | $40.16 | 25,000 | $1,004,000.00 | 8,010 |
See how XENE stacks up against similar companies in the market
Enhance your trading experience with our free tools
The information presented on this page, "XENE Xenon Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.